The further observation from mouse model that mucosal candidiasis was ameliorated by the inhibition of IFN-γ and/or Janus kinase (JAK)/STAT was recently translated into clinical, to evaluate the safety and efficacy of JAK/STAT inhibition in the management of in APECED patients, showing remarkably positive responses to ruxolitinib not only for MCC, but also for alopecia, nail dystrophy, keratitis, steroid-dependent autoimmune hepatitis, exocrine pancreatic insufficiency, renal potassium wasting, hypoparathyroidism, and diabetes insipidus [81▪]. This evidence concerns the gene SOAT1 and hypoparathyroidism.